文献速递肝病

鸟氨酸苯乙酸盐治疗显性肝性脑病的随机试验疗效与安全性

Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-10-16

这项2b期双盲随机对照试验在北美、欧洲、以色列和澳大利亚多中心纳入231例肝硬化伴急性或显性肝性脑病患者,比较鸟氨酸苯乙酸盐(OP,10、15或20 g/d)联合标准治疗与安慰剂联合标准治疗的疗效与安全性。基于当地实验室氨检测,OP组与安慰剂组至临床改善的中位时间无显著差异(P = .129);基于中心实验室确认基线氨升高者(n = 201),OP组临床改善中位时间较安慰剂组提前21小时。严重不良事件发生率OP组25% vs 安慰剂组29%(P = .552)。

要点

  • 基于当地实验室氨检测,OP组与安慰剂组至临床改善中位时间无显著差异(P = .129)。
  • 中心实验室确认基线氨升高者(n = 201)中,OP组临床改善中位时间较安慰剂组提前21小时。
  • 严重不良事件发生率OP组25% vs 安慰剂组29%(P = .552),各组特定不良事件百分比无显著差异。

核心结论

  • 在肝硬化伴肝性脑病患者的随机对照试验中,OP组与安慰剂组至临床改善时间无显著差异。
  • OP似乎安全,作者认为应进一步测试其用于治疗因急性或显性肝性脑病诱因接受治疗的住院患者高氨血症。

研究设计与样本

  • 2b期双盲随机对照试验,2014年1月7日至2016年12月29日在北美、欧洲、以色列和澳大利亚多中心进行。
  • 纳入231例肝硬化伴筛查时氨水平升高及急性或显性肝性脑病患者,随机接受安慰剂或OP(10、15或20 g/d,基于肝病严重程度),均联合各机构标准治疗(如乳果糖以达到2-3次排便,联合或不联合利福昔明,依据指南)。
  • 主要终点为意向治疗人群(筛查时当地实验室确认氨水平升高的所有患者)至确认临床反应的时间,定义为基线HEST 3/4期降至HEST 2期或基线2期改善至HEST 0/1期。

主要发现

  • 基于当地实验室氨检测,OP组与安慰剂组至临床改善的中位时间无显著差异(P = .129)。
  • 中心实验室确认基线氨升高者(n = 201)中,OP组临床改善中位时间较安慰剂组提前21小时。
  • 各组任何特定不良事件百分比无显著差异;严重不良事件发生率OP组25% vs 安慰剂组29%(P = .552)。

关键数值与推荐

  • OP剂量依据肝病严重程度为10、15或20 g/d。
  • 临床反应定义为基线HEST 3/4期降至HEST 2期或基线2期改善至HEST 0/1期。
  • 标准治疗如乳果糖以达到2-3次排便,联合或不联合利福昔明,依据指南。

临床怎么用

  • 作者认为OP似乎安全,应进一步测试其用于治疗因急性或显性肝性脑病诱因接受治疗的住院患者高氨血症。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatic encephalopathy (HE) is associated with increased morbidity, mortality, and health care resource use. In this phase 2b study, we evaluated the efficacy and safety of ornithine phenylacetate (OP), an ammonia scavenger, in hospitalized patients with cirrhosis, increased levels of ammonia at screening, and acute or overt HE. METHODS: We conducted a double-blind study of 231 patients with cirrhosis and HE at multiple sites in North America, Europe, Israel, and Australia from January 7, 2014, through December 29, 2016. Patients were assigned randomly to groups that received placebo or OP (10, 15, or 20 g/d, based on the severity of liver disease), plus each institution's standard of care (eg, lactulose to achieve 2-3 bowel movements with or without rifaximin, in accordance with guidelines). The primary end point was time to confirmed clinical response, defined as reduction to HE staging tool (HEST) stage 2 from baseline HEST stages 3/4 or improvement to HEST stages 0/1 from baseline stage 2, in the intent-to-treat population (all patients with increased levels of ammonia at screening, determined by a local laboratory). RESULTS: Median times to clinical improvement, based on ammonia measurements at local laboratories, did not differ significantly between the groups given OP vs the placebo group (P = .129). Analyses of central laboratory-confirmed increases in levels of ammonia at baseline (n = 201) showed clinical improvement in HE at a median of 21 hours sooner in groups given OP vs placebo. The percentages of patients with any specific adverse event did not differ significantly between groups. Serious adverse events occurred in 25% of patients in the OP group and in 29% in the placebo group (P = .552). CONCLUSIONS: In a randomized controlled trial of patients with cirrhosis and HE, we found no significant difference in time to clinical improvement between patients given OP vs placebo. However, OP appears to be safe and should undergo further testing for treatment of hyperammonemia in hospitalized patients receiving treatment for the underlying precipitant of acute or overt HE. ClinicalTrials.gov no: NCT01966419.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rahimi RS, Safadi R, Thabut D, et al. Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial. Clin Gastroenterol Hepatol. 2020. PMID: 33069881. doi:10.1016/j.cgh.2020.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。